Quantcast

Latest PDL BioPharma Inc. Stories

2014-07-30 08:32:10

INCLINE VILLAGE, Nev., July 30, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that company management will participate in the Jefferies 2014 Boston Healthcare Summit next week in Boston, Massachusetts. The conference will occur on August 6, 2014 and will not be webcast. About PDL BioPharma, Inc. PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements...

2014-07-28 08:28:47

INCLINE VILLAGE, Nev., July 28, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2014 financial results for the period ended June 30, 2014, on Monday, August 11, 2014, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL...

2014-06-24 08:29:53

INCLINE VILLAGE, Nev., June 24, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will participate in the following conferences this week. JMP Securities Healthcare ConferenceWednesday, June 25, 20141:00 p.m. EDTNew York, NYWill be webcast Janney Capital Markets Boston Healthcare 1x1 Corporate Access DayThursday, June 26, 2014Boston, MAWill not be webcast To access the live and...

2014-06-12 16:26:18

INCLINE VILLAGE, Nev., June 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 5, 2014, the record date. About PDL BioPharma PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and...

2014-06-10 16:27:04

INCLINE VILLAGE, Nev., June 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2014, of approximately $140 million, as compared with actual revenue of $143.6 million for the second quarter of 2013, an approximate 3 percent decrease. The forecasted revenues are driven by increased first quarter 2014 sales for Avastin(®), Herceptin(®), Xolair(®), Kadcyla(®), Perjeta(®) and Actemra(®) for which PDL...

2014-06-04 16:25:59

INCLINE VILLAGE, Nev., June 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: -- 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 165.4367 shares of common stock per $1,000 principal amount or approximately $6.04 per share, effective June 3, 2014? and -- 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes), is 188.812 shares of...

2014-05-29 16:26:42

INCLINE VILLAGE, Nev., May 29, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference next week in New York City. The presentation, which will be webcast, will occur on Thursday, June 5, 2014 at 8:30 a.m. EDT. To access the live and subsequently archived webcast of the presentation, go to the Company's website at...

2014-05-12 16:28:47

-Revenues Increased 52 Percent- INCLINE VILLAGE, Nev., May 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2014. Total revenues for the first quarter of 2014 increased 52 percent to $139.7 million from $91.8 million in the first quarter of 2013. Royalty revenues for the first quarter of 2014 are based on fourth quarter 2013 product sales by PDL's licensees to the Queen et al. patents, royalty...

2014-05-08 16:26:41

Conference call scheduled for today at 5:00 p.m. EDT NEWARK, Calif., May 8, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO), today reported financial results for the first quarter ended March 31, 2014. First Quarter 2014 Business Highlights -- Relaunched migraine product CAMBIA(®) (diclofenac potassium for oral solution) in February 2014 -- Achieved settlements with two of the three defendants in the Gralise(®) (gabapentin) patent litigation in April 2014...

2014-05-08 08:32:17

INCLINE VILLAGE, Nev., May 8, 2014 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Peter Garcia, the company's vice president and chief financial officer, will present at the Bank of America Merrill Lynch Health Care Conference next week in Las Vegas, Nevada. The presentation, which will be webcast, will occur on Thursday, May 15, 2014, at 12:40 p.m. PDT. http://photos.prnewswire.com/prnvar/20110822/SF55808LOGO To access the live and subsequently...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related